Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer.

Research output: Contribution to journalArticle


Putative biomarkers of gemcitabine response have been extensively studied in pancreatic cancer, but less so in other types of periampullary adenocarcinoma. The most studied biomarker is human equilibrative nucleoside transporter 1 (hENT1), and the activating enzyme deoxycytidine kinase (dCK) has also been linked to treatment response. The RNA-binding protein human antigen R (HuR) has been demonstrated to confer increased dCK levels in vitro and to predict gemcitabine response in vivo. Here, we investigated the prognostic impact of hENT1, dCK and HuR in pancreatobiliary (PB) and intestinal (I) type periampullary cancers, respectively.


Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cancer and Oncology
Original languageEnglish
Pages (from-to)286-96
JournalActa oncologica (Stockholm, Sweden)
Issue number3
Early online date2015
Publication statusPublished - 2016
Publication categoryResearch

Related research output

Jacob Elebro, 2016, Lund: Lund University, Faculty of Medicine. 83 p.

Research output: ThesisDoctoral Thesis (compilation)

View all (1)